Tafamidis 80 mg is more likely to improve disease measures than placebo in patients with transthyretin amyloid cardiomyopathy

Franca S. Angeli

Richard Y. Zhang

Maria G. Crespo-Leiro

0 views
0 downloads

Powered byMorressier logo black

Discover more research and events on morressier.com